eligibility_summary
Adults 18–70 with advanced solid tumors after 1–2 prior lines, measurable disease (RECIST), ECOG 0–1, >12‑week survival, adequate marrow/organ function, prior toxicities resolved, venous access, contraception, consent. Exclude: recent/active second cancers, transplant, unstable CNS mets, variceal/major bleeding, recent thrombosis, uncontrolled CV disease/QTc>500, serious lung/infectious/autoimmune disease, recent therapy/radiation/surgery/trials/vaccines, pregnancy/breastfeeding, allergy, or high risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: CNK-UT, a biological cell therapy consisting of universal chimeric natural killer receptor–modified T cells (CAR-T–like) engineered to dual-target NKG2D ligands and NCR2/NKp44 ligands. Mechanism: The engineered T cells use NK-derived activating receptors fused to T-cell signaling domains to recognize stress-induced tumor ligands and trigger T-cell cytotoxicity and cytokine release, optional lymphodepletion (fludarabine/cyclophosphamide) may enhance expansion/persistence. Cells/pathways targeted: Tumor cells expressing NKG2D-ligand pathways (stress/transformational ligands such as MICA/MICB/ULBPs) and NKp44-ligand pathways broadly upregulated in solid tumors, leveraging innate stress-recognition to address heterogeneity in advanced solid tumors.